







an Open Access Journal by MDPI

Oral Cancer and COVID-19

Guest Editor:

Dr. Francesco D'Ambrosio

Department of Medicina and Surgery, Schola Medica Salernitana, Via Salvador Allende, Baronissi, Italy

Deadline for manuscript submissions:

1 July 2024

Message from the Guest Editor

Dear Colleagues,

Cancer is one of the leading diseases causing death in industrialized countries, despite numerous prevention campaigns and recent advances in medical treatments.

The etiopathogenesis of cancer is varied, but it seems that some viruses may also be implicated.

COVID-19 is a disease caused by the SARS-Cov-2 virus. Some authors have highlighted that the SARS-CoV-2 virus penetrates the host cell using cellular receptors of the angiotensin converting enzyme 2 (ACE2), which are well expressed in the oral mucosa and the EMMPRIN receptor, the inducer of extracellular matrix metalloproteinase.

It appears that the two potential receptors of SARS-CoV-2, ACE2 and EMMPRIN have effects on the progression of oral tumors.

Dr. Francesco D'Ambrosio Guest Editor













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us